For these studies, one group of 5XFAD mice (n = 8) was given ad libitum access to Riluzole solution, i.e., 13 mg/kg per mouse per day, a dose that has previously been reported to improve cognition and reduce tau pathology in P301L tau AD mice5 (link),17 , from 1 to 6 months of age (total treatment duration = 5 months). A control group of 5XFAD mice (n = 7) and the wild-type (WT) mice (n = 10) had ad libitum access to tap water. For immunohistochemical studies, a separate batch of 5XFAD mice was treated with Riluzole (n = 5) or tap water as control (n = 5). We chose sample sizes based on past literature utilizing these methodologies4 (link),7 (link),18 (link)–20 (link) with the intention to minimize the number of animals to be used for the present study.
Riluzole (R116; Sigma-Aldrich, St Louis, MO, USA) was dissolved in room temperature tap water at a stock concentration of 0.12 mg/ml and stirred for ~6 h, covered by foil to prevent light exposure. The stock solution was diluted into the mouse drinking water based on (1) average animal weight and, (2) water consumption over the previous 24 h period and throughout the study, which was measured by weighing the water bottles. We prepared fresh Riluzole solution after every 2nd to 3rd day during the entire treatment period.
Riluzole (R116; Sigma-Aldrich, St Louis, MO, USA) was dissolved in room temperature tap water at a stock concentration of 0.12 mg/ml and stirred for ~6 h, covered by foil to prevent light exposure. The stock solution was diluted into the mouse drinking water based on (1) average animal weight and, (2) water consumption over the previous 24 h period and throughout the study, which was measured by weighing the water bottles. We prepared fresh Riluzole solution after every 2nd to 3rd day during the entire treatment period.
Free full text: Click here
